- 英文名称
- Valrubicin
- 分子式
- C34H36F3NO13
- 分子量
- 723.64
- 中文别名
- 戊柔吡星; 缬柔比星; 2-氧代-2-((2S,4S)-2,5,12-三羟基-4-(((2R,4S,5S,6S)-5-羟基-6-甲基-4-(2,2,2-三氟乙酰氨基)四氢-2H-吡喃-2-基)氧基)-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢并四苯-2-基)乙基 戊酸酯; 戊酸2-氧代-2-((2S,4S)-2,5,12-三羟基-4-(((2R,4S,5S,6S)-5-羟基-6-甲基-4-(2,2,2-三氟乙酰氨基)四氢-2H-吡喃-2-基)氧基)-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢并四苯-2-基)乙酯; 2-oxo-2-((2S,4S)-2,5,12-trihydroxy-4-(((2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetamido)tetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethyl pentanoate; 2-Oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydro-2-tetracenyl]ethyl valerate; 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate; N-trifluoroacetyladriamycin-14-valerate; Pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester; trifluoroacetyl-adriamyci14-valerate; N-(trifluoroacetyl)adriamycin 14-valerate (AD 32); 2-Oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl valerate; N-Trifluoroacetyldoxorubicin 14-valerate; ad32; N-Trifluoroacetyladriamycin 14-valerate; Valstar; (2S-cis)-Pentanoic Acid 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-a-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl Ester; N-trifluoroacetyldoxorubicin-14-valerate; antibioticad32; nsc-246131; n-trifluoroacetyladriamycin14-valerate; n-trifluoroacetyldoxorubicin14-valerate; trifluoroacetyladriamycin-14-valerate
- 用途
- 化学合成;作为蒽环类化疗药物,用于治疗难治性膀胱原位癌;通过干扰正常DNA的分裂重组影响细胞生物学功能,干涉核酸代谢,抑制核苷形成核酸,引起大量染色体损伤并使细胞周期停止于G2期;可抑制TPA-和PDBu-诱导的PKC活化,IC50值分别为0.85μM和1.25μM;在抗鳞状细胞癌(SCC)细胞系集落形成实验中显示细胞毒性活性;与放射治疗联用可增强细胞毒作用;可减少仓鼠肿瘤生长;可减少小鼠急性炎症模型中浸润的中性粒细胞数量并降低炎症细胞因子表达水平